Global Flecainide Market is expected to grow at a CAGR of 3.2% from 2020 to 2027

Flecainide is classified as a class 1 antiarrhythmic drug which received USFDA approval in 1985 for the treatment of atrial fibrillation and ventricular tachycardia. It causes the inhibition of the sodium and potassium ion channels in the heart causing an increase in the heart threshold for depolarization and correcting arrhythmias. It is available in doses of 50,100 and 150mg tablets for the treatment of different severity of cardiac arrhythmias. Supraventricular tachycardia is presently leading the indication segment for the flecainide market. The chief causative agents for its clinical manifestations are…

Read More